BR0116686A - Anticorpos anti-cd28 silenciados e uso dos mesmos - Google Patents
Anticorpos anti-cd28 silenciados e uso dos mesmosInfo
- Publication number
- BR0116686A BR0116686A BR0116686-7A BR0116686A BR0116686A BR 0116686 A BR0116686 A BR 0116686A BR 0116686 A BR0116686 A BR 0116686A BR 0116686 A BR0116686 A BR 0116686A
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- usage
- silenced
- silenced anti
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25515500P | 2000-12-14 | 2000-12-14 | |
PCT/US2001/047955 WO2002047721A1 (en) | 2000-12-14 | 2001-12-14 | Silensed anti-cd28 antibodies and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0116686A true BR0116686A (pt) | 2003-12-30 |
Family
ID=22967074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0116686-7A BR0116686A (pt) | 2000-12-14 | 2001-12-14 | Anticorpos anti-cd28 silenciados e uso dos mesmos |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1341553A4 (cs) |
JP (1) | JP2004515243A (cs) |
KR (1) | KR20040020866A (cs) |
CN (1) | CN1272345C (cs) |
AR (1) | AR031924A1 (cs) |
AU (2) | AU2002226086C1 (cs) |
BR (1) | BR0116686A (cs) |
CA (1) | CA2432736A1 (cs) |
CZ (1) | CZ20031909A3 (cs) |
HU (1) | HUP0400697A3 (cs) |
IL (1) | IL156262A0 (cs) |
MX (1) | MXPA03005327A (cs) |
NO (1) | NO20032542L (cs) |
NZ (1) | NZ526569A (cs) |
PL (1) | PL363239A1 (cs) |
RU (1) | RU2261723C2 (cs) |
WO (1) | WO2002047721A1 (cs) |
ZA (1) | ZA200305384B (cs) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
FR2951176A1 (fr) * | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
US8785604B2 (en) * | 2010-02-18 | 2014-07-22 | Effimune | Anti-CD28 humanized antibodies |
CN114917185B (zh) | 2016-10-21 | 2023-11-14 | 美国安进公司 | 药物配制品及其制备方法 |
WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
US20220153845A1 (en) * | 2019-03-14 | 2022-05-19 | Biond Biologics Ltd. | A method for immunosuppression |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
MX2023001962A (es) | 2020-08-19 | 2023-04-26 | Xencor Inc | Composiciones anti-cd28. |
WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
WO2024148336A1 (en) * | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | T cell costimulatory multimeric binding molecules and uses thereof |
WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
-
2001
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/es unknown
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/ru not_active IP Right Cessation
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 PL PL01363239A patent/PL363239A1/xx not_active Application Discontinuation
- 2001-12-14 AR ARP010105828A patent/AR031924A1/es unknown
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/ko not_active Application Discontinuation
- 2001-12-14 AU AU2608602A patent/AU2608602A/xx active Pending
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 CN CNB018226361A patent/CN1272345C/zh not_active Expired - Fee Related
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/hu unknown
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/cs unknown
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/ja not_active Withdrawn
- 2001-12-14 IL IL15626201A patent/IL156262A0/xx unknown
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Application Discontinuation
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/pt not_active IP Right Cessation
-
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/no not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0400697A3 (en) | 2007-05-02 |
NO20032542L (no) | 2003-08-07 |
CZ20031909A3 (cs) | 2003-11-12 |
KR20040020866A (ko) | 2004-03-09 |
RU2261723C2 (ru) | 2005-10-10 |
ZA200305384B (en) | 2004-10-11 |
EP1341553A1 (en) | 2003-09-10 |
WO2002047721A1 (en) | 2002-06-20 |
AU2608602A (en) | 2002-06-24 |
MXPA03005327A (es) | 2004-12-03 |
CA2432736A1 (en) | 2002-06-20 |
AU2002226086C1 (en) | 2006-03-09 |
PL363239A1 (en) | 2004-11-15 |
CN1489473A (zh) | 2004-04-14 |
HUP0400697A2 (hu) | 2004-06-28 |
NO20032542D0 (no) | 2003-06-05 |
EP1341553A4 (en) | 2004-07-28 |
NZ526569A (en) | 2005-07-29 |
AU2002226086B2 (en) | 2005-08-25 |
JP2004515243A (ja) | 2004-05-27 |
RU2003121231A (ru) | 2005-02-10 |
IL156262A0 (en) | 2004-01-04 |
CN1272345C (zh) | 2006-08-30 |
AR031924A1 (es) | 2003-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0116686A (pt) | Anticorpos anti-cd28 silenciados e uso dos mesmos | |
ATE412432T1 (de) | Internalisierende erbb2 antikörper | |
DE69129302D1 (de) | Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen | |
ES2293973T3 (es) | Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos. | |
CR10878A (es) | Anticuerpos para cd40 (divisional de exp. 7343) | |
RS80704A (en) | ANTI- av?6.ANTIBODIES | |
EA200300464A1 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ | |
BR0314814A (pt) | Variantes otimizadas de fc e métodos para sua geração | |
PT1315520E (pt) | Utilizacao de anticorpos trifuncionais biespecificos e triespecificos para tratamento de ascites malignas | |
BR9606706A (pt) | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo | |
DE60226797D1 (de) | Instrument zum Einbringen von Befestigungselementen für Transplantate | |
DE69619493D1 (de) | Polypeptid-dendrimer komplexe | |
ATE248605T1 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
ATE255906T1 (de) | Antikörper gegen cd40 | |
BR0309873A (pt) | Pirazolo-pirimidin-4-onas substituìdas | |
DK0973550T3 (da) | Antagonistiske anti-AVB3-integrin-antistoffer | |
WO2000002917A3 (en) | Compounds and methods for modulating cadherin-mediated functions | |
BR0210965A (pt) | Conjugado de quelador, complexo de radiometal, radiofármaco, kit para a preparação do mesmo, composto, e, processo para a preparação do mesmo | |
ATE395364T1 (de) | Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung | |
BRPI0405450A (pt) | Agente de revestimento | |
DE69837387D1 (de) | (d)-METHADON, EIN NICHT-OPIOIDES SCHMERZMITTEL | |
DE69814007D1 (de) | Magnetverschluss insbesondere für Kleidungstücke | |
ATE202117T1 (de) | Angiotensin ii rezeptor typ i spezifische monoklonale antikörper und hybridoma | |
BR0015872A (pt) | Agentes antitrombóticos | |
WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO. LTD. |
|
B25D | Requested change of name of applicant approved |
Owner name: ASTELLAS PHARMA INC. (JP) Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009. |